Kong Lingti, Rong Li, Xie Mengyuan, Wang Muhua
Department of Pharmacy, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
School of Pharmacy, Bengbu Medical College, Bengbu, China.
Saudi Pharm J. 2023 Jan;31(1):180-183. doi: 10.1016/j.jsps.2022.11.016. Epub 2022 Dec 1.
Studies have proved that UGT1A1 (*6, *28 and *93) gene polymorphism was closely related to the side effects of irinotecan. This study intends to perform a correlation analysis on the relationship between pharmacogenomic studies and ADRs based on time series.
The ADRs related to irinotecan were derived through the FAERS; searched all pharmacogenomic studies in PubMed and Web of Science; then analyzed the sequence of correlation coefficients between total ADRs, fatal ADRs and pharmacogenomic studies under different time offset.
There is a positive correlation between the number of total ADRs and pharmacogenomic studies, of which the maximum correlation coefficient was 0.78 (95 % CI: 0.58-0.90), with a lag of 1 year. There is also a positive correlation between the number of fatal ADRs and pharmacogenomic studies, with the maximum correlation coefficient of 0.87 (95 % CI: 0.73-0.94) and a offset of - 4 years.
It was found that both the total ADRs and fatal ADRs were significantly positively correlated with change trend of published pharmacogenomic literatures, which confirmed the role of pharmacogenomic research in promoting the safe use of irinotecan, and have a faster response time in reducing fatal ADRs during clinical application.
研究已证明UGT1A1（*6、28和93）基因多态性与伊立替康的副作用密切相关。本研究旨在基于时间序列对药物基因组学研究与药物不良反应之间的关系进行相关性分析。
通过FAERS获取与伊立替康相关的药物不良反应；在PubMed和Web of Science中检索所有药物基因组学研究；然后分析不同时间偏移下总药物不良反应、致命药物不良反应与药物基因组学研究之间的相关系数序列。
总药物不良反应数量与药物基因组学研究之间存在正相关，其中最大相关系数为0.78（95%CI：0.58 - 0.90），滞后1年。致命药物不良反应数量与药物基因组学研究之间也存在正相关，最大相关系数为0.87（95%CI：0.73 - 0.94），偏移为 - 4年。
发现总药物不良反应和致命药物不良反应均与已发表的药物基因组学文献的变化趋势显著正相关，这证实了药物基因组学研究在促进伊立替康安全使用中的作用，并且在临床应用中减少致命药物不良反应方面具有更快的响应时间。
